Peptide Partners LLC – FDA Warning Letter, Aug 3, 2026

The FDA issued a Warning Letter to Peptide Partners LLC on August 24, 2026, following a July 2026 review of the company"s website. The investigation revealed that the firm is illegally marketing several products—including Semaglutide, Tirzepatide, Retatrutide, Elamipretide, Tesamorelin, and Bremelanotide—as treatments for serious medical conditions such as diabetes, obesity, Alzheimer’s, and cancer. Under the Federal Food, Drug, and Cosmetic (FD&C) Act, these items are classified as drugs because they are intended to mitigate or treat diseases. However, they are considered unapproved new drugs because they have not undergone the required FDA safety and efficacy reviews. The FDA highlighted that these injectable products are particularly concerning because they bypass the body’s natural defenses, posing significant health risks if they contain toxins or microorganisms. Furthermore, the company’s sale of a reconstitution solution reinforces the intent for human injection, regardless of "research use only" disclaimers on the labels. To comply with federal law, Peptide Partners LLC must investigate the root causes of these violations and implement corrective measures. The company is required to submit a written response within 15 business days detailing its plan to address these issues and prevent their recurrence. Failure to comply may lead to legal actions, including product seizures or court-ordered injunctions.